Dr. Ameline Lim completed her PhD at the University of New South Wales. Her research focused on using mass spectrometry to characterise a lipid enzyme inhibitor on human and mouse lipidome. Her extensive training led her to a postdoctoral study involving phase II clinical trials, gaining valuable insights into the clinical research environment. She subsequently joined Prince of Wales Hospital Chemical Pathology lab where she was the second in charge of the mass spectrometry unit gaining skills in diagnostic lab operations and analytical method development.
Ameline is passionate about leveraging her skills and experience to drive impactful innovations in research and healthcare industries.
